What are the adverse effects of levothyroxine, particularly those due to overtreatment, and what steps should be taken to evaluate and manage them?

Levothyroxine Side Effects

The most clinically significant adverse effects of levothyroxine are primarily due to overtreatment (iatrogenic hyperthyroidism), which can cause serious cardiovascular complications including atrial fibrillation, myocardial infarction, and arrhythmias, as well as osteoporosis and fractures—particularly in elderly and postmenopausal women. 1

Primary Adverse Effects from Overtreatment

The FDA drug label explicitly lists adverse reactions associated with levothyroxine therapy as primarily those of hyperthyroidism due to therapeutic overdosage 1:

• Cardiovascular: Arrhythmias, myocardial infarction, dyspnea, angina, increased cardiac wall thickness
• Neuropsychiatric: Headache, nervousness, irritability, insomnia, tremors
• Musculoskeletal: Muscle spasm, muscle weakness, myalgia
• Metabolic: Increased appetite, weight loss, heat intolerance
• Other: Diarrhea, menstrual irregularities, skin rash

Critical Clinical Context: The Overtreatment Problem

Approximately 25% of patients receiving levothyroxine are inadvertently maintained on doses high enough to make TSH levels undetectable, which significantly increases risk for serious complications 2. This is particularly concerning because:

• Cardiovascular morbidity: Elderly patients (>60 years) with suppressed TSH have a 2.8-fold increased risk of atrial fibrillation 3
• Bone health: Postmenopausal women with suppressed TSH experience accelerated bone loss, increased fracture rates, and decreased bone mineral density 3, 4
• Long-term consequences: Chronic overdosing may increase risk for osteoporosis, fractures, abnormal cardiac output, or ventricular hypertrophy 2

Dose-Dependent Risk Pattern

Recent evidence demonstrates a clear dose-dependent relationship between levothyroxine dose and suboptimal treatment 5:

• Patients on >150 µg daily have >45% incidence of out-of-range TSH within 6 months
• Higher doses (>100 µg) carry significantly increased risk of both under- and overtreatment
• Hazard ratios for suboptimal treatment increase progressively: 1.58 (51-100 µg), 2.73 (101-150 µg), and 3.08 (>150 µg) 5

Newly Identified Adverse Events

Post-marketing surveillance has identified additional adverse events not originally listed in prescribing information 6:

• Dizziness and depression
• Myalgia and migraine (with established causal relationship via Mendelian randomization)
• Celiac disease and lactose intolerance (causal relationship confirmed)
• Autoimmune thyroiditis
• Nail disorders

Management Algorithm

1. Prevention of Overtreatment

• Target TSH should be maintained above 1 mIU/L to prevent iatrogenic thyrotoxicosis 7
• In elderly patients (>65 years), use age-adjusted TSH targets: upper limit of 7 mIU/L for ages 70-79 and 8 mIU/L for >80 years 7
• Never aim for suppressed TSH unless treating thyroid cancer 7

2. Monitoring Strategy

• Check TSH 6-8 weeks after any dose change 7
• Once stable, annual monitoring is sufficient 7
• Patients on >100 µg require more frequent surveillance due to higher risk of suboptimal treatment 5
• Elderly patients and those with cardiovascular disease need closer monitoring 4

3. Special Population Considerations

Elderly patients (>50-60 years):

• Start at 50 µg daily (or 12.5-25 µg if known coronary heart disease) 4
• Require 20-25% less per kilogram than younger patients 4
• Monitor closely for anginal symptoms and atrial fibrillation 3, 4

Postmenopausal women:

• Particularly susceptible to accelerated bone loss with overtreatment 4
• Maintain TSH in normal range to prevent skeletal complications

4. When Overtreatment Occurs

• Reduce dose or temporarily discontinue if signs/symptoms of overdosage appear 1
• Initiate supportive treatment as dictated by clinical status 1
• Severe overdose can cause confusion, disorientation, seizures, cerebral embolism, shock, coma, or death 1

Critical Pitfalls to Avoid

1. Do not treat to low-normal or suppressed TSH in non-cancer patients—this is the primary cause of iatrogenic complications 2, 7

2. Do not ignore cardiovascular risk factors—elderly patients and those with underlying heart disease are at highest risk for serious cardiac adverse events 3, 4

3. Do not assume all symptoms are drug-related—in euthyroid patients on appropriate replacement doses, blinded placebo-controlled trials show no significant differences in subjective symptoms, suggesting placebo/nocebo effects 8

4. Do not overlook medication interactions—many drugs affect levothyroxine absorption and may necessitate dose adjustments 1

5. Do not continue high doses without justification—patients on >200 µg daily with persistently elevated TSH likely have compliance or absorption issues rather than true resistance 4

Evidence Quality Note

The evidence base for levothyroxine harms is notably limited. The FDA approval process in 2000 did not include studies evaluating short- or long-term adverse effects 2. Most trials assessing harms were not designed or powered to evaluate long-term or serious complications 2. However, the consistent guideline recommendations and post-marketing data provide sufficient evidence to prioritize prevention of overtreatment as the primary safety concern.